6547 on Taipei Exchange
Logo: medigenvac.com3
Company based in Zhubei, Hsinchu County, Taiwan
The Medigen Vaccine Biologics Corporation (MVC; traditional Chinese: 高端疫苗生物製劑; simplified Chinese: 高端疫苗生物制剂; pinyin: Gāoduān Yìmiáo Shēngwù Zhìjì) is a pharmaceutical company headquartered in Neihu, Taipei, Taiwan.2 Its shares trade on Taipei Exchange under the symbol 6547.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
See how the biggest companies compare on our leaderboards
The Medigen Vaccine Biologics Corporation (MVC; traditional Chinese: 高端疫苗生物製劑; simplified Chinese: 高端疫苗生物制剂; pinyin: Gāoduān Yìmiáo Shēngwù Zhìjì) is a pharmaceutical company headquartered in Neihu, Taipei, Taiwan.2
The company was founded in October 2012. During the COVID-19 pandemic in Taiwan, the company produces the MVC COVID-19 vaccine to fight the virus.
On 18 March 2026, Vietnam's Ministry of Health has approved the rollout of the Medigen enterovirus vaccine in Vietnam, which is the company's first overseas rollout.
From Wikipedia’s article on Medigen Vaccine Biologics Corporation, shared under CC BY-SA 4.0.4
The company has a manufacturing plant in Hsinchu Biomedical Science Park, Zhubei City, Hsinchu County.
From Wikipedia’s article on Medigen Vaccine Biologics Corporation, shared under CC BY-SA 4.0.4
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
The numbers on this page point here. Each one links to the record it came from.
.jpg){kind=link}